Sonendo, Inc.

SONX
About the company

Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment technology platform designed for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure.

Country: United StatesPrice: $1.28Market Cap: $6.1M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

1 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #3016 (Top 97.4%)PASSFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2024

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-03-26

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 9✗ 19▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.1x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-284.8%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-284.8%, ROC=-347.9%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.1x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-406.8%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.1x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low5818% of trailing low ($0.02)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-459.62%; #5905/6340 (top 93.1%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.8511; #1801/6449 (top 27.9%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share0.11x
      ✓SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+5.4434; #506/5247 (top 9.6%)
      ✓OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-406.83%; #4318/4519 (top 95.6%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+156.00%; #199/6202 (top 3.2%)
      ✓OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing$-24.8M
      ✗LynchPositive and growing
      Operating Cash Flow$-24.7M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-78.85%, ROA=-89.66%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-406.8%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/5 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-4535.6%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/5 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-24.8M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-406.83%; #4318/4519 (top 95.6%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -7.8% vs Rev: -24.3%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/5 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth5.3%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 25.2% -> 35.7%, operating margin -139.7% -> -88.5%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✓ 1✗ 10▾

      No clean pass — all 8 investors flag at least one efficiency criterion

      Current Ratio1.39
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-158.4%
      ✗Buffett> 10%
      ROIC - WACC-168.4%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-347.9%
      ✗Greenblatt> 25%
      Current Ratio Change YoY1.85 -> 1.39
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.56x -> 1.06x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities1.39
      ✗Dreman> 1.5
      Return on Invested Capital-118.2%
      ✗Munger> 15%
      ROIC (high and growing)FY2022: ROIC=-38.7%; FY2023: ROIC=-71.2%; FY2024: ROIC=-118.2%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/4 years above 12% (latest -118.2%)
      ✗SleepROIC > 12% in a majority of years
    • Profitability6% pass✓ 6✗ 29▾

      15 of 16 flag SONX's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/6 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/6 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-222.8%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-88.5% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-540.0%
      ✗Lynch> 15%
      EBIT / Enterprise Value-284.8%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-284.8%, ROC=-347.9%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-89.66%
      ✗PiotroskiROA > 0
      ROA Change YoY-77.94% -> -89.66% (delta: -11.72%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-78.85%, ROA=-89.66%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY10.6% -> 35.7%
      ✓PiotroskiImproved YoY
      Pre-Tax Income / Revenue-101.0%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-540.0%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.1x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-274.7% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/5 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-88.5%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-540.0%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-139.7% (2022) -> -88.5% (2024)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 25.2% -> 35.7%, operating margin -139.7% -> -88.5%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-459.62%; #5905/6340 (top 93.1%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+37.88%; #1036/3702 (top 28.0%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity-540.03%; #5081/5226 (top 97.2%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.1917; #4192/5884 (top 71.2%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/5 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts6% pass✓ 1✗ 15▾

      Split decision: 14 FAIL · 1 PASS · 1 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #3016✓PiotroskiPASS (F-Score 5)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #1632/2370 (Top 68.9%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage17% pass✓ 3✗ 12▾

      10 of 12 flag SONX's debt & leverage — Buffett, Lynch, Dreman +7 more

      LT Debt vs Net Current AssetsLT Debt $3.6M vs NCA $7.9M
      ✓GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 2.78, IC: -8.5x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity2.78
      ✗Lynch< 0.33
      Cash - Long-term Debt$6.6M
      ✓LynchPositive preferred
      LT Debt / Total Assets Change15.95% -> 11.63%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities1.39
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity2.78
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels2.78
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-8.5x, D/EBITDA=N/A (D&A unavailable)
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity2.78
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-2.7812; #3903/4210 (top 92.7%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($6.1M)
    Revenue: $33.2M-24.3% YoY
    Net Income: $28.0M+54.0% YoY

    Financial Snapshot

    Operating Margin-88.5%
    Return on Equity-540.0%
    Debt / Equity2.78
    Current Ratio1.39
    EPS (Diluted)$-59.03

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2024-12-31

    2024-01-01 – 2024-12-31

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense.

    Q4 FY 2024

    2024-10-01 – 2024-12-31

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, capex.

    Q3 FY 2024

    2024-07-01 – 2024-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q2 FY 2024

    2024-04-01 – 2024-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2024

    2024-01-01 – 2024-03-31

    Sources
    FY 2024
    Sources
    • 10-K · 2025-03-26
    FY 2023
    Sources
    • 10-K · 2024-03-11
    FY 2022
    Sources
    • 10-K · 2023-03-08
    FY 2021
    Sources
    • 10-K · 2022-03-23
    FY 2020
    Sources
    • 10-K · 2022-03-23
    Market Cap$6.1Mcurrent--------$1.0Mest.$2.0Best.$26.5Best.$8.2Best.$2.2Best.
    Revenue$31.7M$8.3M$8.0M$8.3M$7.0M$33.2M↓24%$43.9M↑5%$41.7M↑25%$33.2M↑42%$23.4M
    Operating Income-$29.4M-$5.6M-$6.8M-$6.7M-$10.2M-$29.4M↑50%-$59.3M↓2%-$58.2M↓31%-$44.4M↓4%-$42.8M
    Net Income-$28.0M-$6.4M-$7.5M-$7.4M-$6.8M-$28.0M↑54%-$60.9M↓7%-$57.0M↓18%-$48.5M↓4%-$46.7M
    EPS (Diluted)----$-15.77$-0.08$-0.07$-59.03↓8982%$-0.65↑49%$-1.27↑85%$-8.52↑78%$-39.02
    Gross Margin37.4%41.1%41.2%37.5%28.4%35.7%↑235%10.6%↓58%25.2%25.1%↑51%16.6%
    Operating Margin-92.6%-67.9%-84.5%-80.4%-145.4%-88.5%↑35%-135.1%↑3%-139.7%↓4%-133.8%↑27%-183.3%
    ROE-540.0%————-540.0%↓152%-214.4%↓208%-69.6%↓3%-67.3%↓466%18.4%
    Total Debt$14.4M$14.4M$16.9M$19.3M$21.7M$14.4M↓61%$37.4M↑2%$36.8M↑39%$26.6M↓7%$28.5M
    Shareholders' Equity$5.2M$5.2M$11.0M$17.9M$24.5M$5.2M↓82%$28.4M↓65%$82.0M↑14%$72.1M↑128%-$253.9M
    Current Ratio1.391.391.822.402.781.39↓25%1.85↓74%7.24↑7%6.75↑367%1.44
    Debt / Equity2.782.781.541.080.892.78↑112%1.31↑193%0.45↑22%0.37↑428%-0.11
    Operating Cash Flow-$24.7M-$2.9M-$4.3M-$6.7M-$10.7M-$24.7M↑46%-$46.1M↑25%-$61.1M↓26%-$48.6M↓26%-$38.5M
    Free Cash Flow-$24.8M-$2.9M-$4.3M-$6.7M-$10.8M-$24.8M↑47%-$47.0M↑25%-$62.4M↓27%-$49.2M↓25%-$39.5M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    SONX vs Peers — Financial Grading

    Revenue$33.2MBottom 25%
    Net Income$28.0MBottom 25%
    ROE-540.0%Bottom 25%
    D/E2.78Bottom 25%
    Op. Margin-88.5%Bottom 25%
    Curr. Ratio1.39Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11